Nicolas Barthelemy is a life science industry veteran with 25 years of diverse expertise. He brings extensive experience in manufacturing, distributing and commercializing life science instruments, reagents and services, and knowledge of the research, clinical and bioprocessing markets as well as his public and private board experience. Mr. Barthelemy previously served as the President and Chief Executive Officer of Biotheranostics, Inc., a Molecular Diagnostics company. Prior to joining Biotheranostics, he held a variety of senior executive roles at Life Technologies until its acquisition by Thermo Fisher Scientific, including Chief Commercial Officer and President of the Cell Systems Division. Prior to joining Invitrogen (which later became Life Technologies), Mr. Barthelemy held a variety of operational and commercial roles with Biogen, Inc., including Vice President of Manufacturing. Before that, he held various technical positions at Merck & Co’s manufacturing division. Mr. Barthelemy currently serves on the board of directors of Repligen, Fluidigm and Genewiz and has previously served on the board of directors of Essen Bioscience. He holds an engineering degree from École Supérieure de Physique et Chimie Industrielles, France, as well as a master’s degree in chemical engineering from the University of California, Berkeley.